ERBB2 and breast cancer: Better blood-brain barrier penetrating small tyrosine kinase inhibitors were subsequently developed after first generation trastuzumab and include lapatinib, afatinib, epertanib, neratinib tucatinib, pyrotinib and are used as systemic targeted therapy for patients with HER-2 positive breast cancer (53).